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PHARMACOGENETIC STUDIES ON THE DRUG- 
RELATED LUPUS SYNDROME 
Differences in Antinuclear Antibody Development and Drug-Induced DNA 
Damage in Rapid and Slow Acetylator Animal Models 
W. W. WEBER and R. H. TANNEN 
Pharmacogenetic study of an inbred mouse 
model system derived from A/J (slow acetylator) and 
C57BL/6J (rapid acetylator) parental strains shows 
that spontaneous occurrence of antinuclear antibodies 
is associated with the slow acetylator phenotype al- 
though the development of spontaneous and pro- 
cainamide-induced antinuclear antibodies is a dis- 
sociable process. In another study using primary 
cultures of intact hepatocytes obtained from slow and 
rapid acetylator rabbits, observations indicate that the 
amount of DNA damage induced by exposure to hydra- 
zine and arylamine containing foreign compounds de- 
pends on the concentration of the foreign compound 
used as well as on the acetylator phenotype. Exposure 
to hydralazine induced greater DNA damage in slow 
acetylator hepatocytes whereas exposure to the aryla- 
mine carcinogen, 2-aminofluorene, induced greater 
DNA damage in rapid acetylator hepatocytes. 
A lupus erythematosus-like syndrome is some- 
times seen in patients receiving therapeutic doses of 
hydralazine, procainamide (PA), or isoniazid (1). Each 
of these drugs contains either a hydrazine or an aryla- 
mine group which undergoes N-acetylation, an impor- 
tant early step in their elimination from the body (2-6). 
Persons with a low capacity for N-acetylation, such as 
phenotypic slow acetylators, are more likely to develop 
drug-induced lupus or some manifestations of this dis- 
order from these drugs than rapid acetylators (7). Slow 
acetylators may also be found in abnormally high num- 
bers in certain groups of patients with spontaneous 
lupus erythematosus (8). These correlations have sug- 
gested more than a simple pharmacologic relation be- 
tween drug-induced lupus and the slow acetylator 
phenotype and we have devised new experimental ap- 
proaches to seek such possibilities. 
We have found from pharmacogenetic studies in 
an inbred mouse model system that spontaneous occur- 
rence of antinuclear antibodies (ANA) is associated 
with the slow acetylator phenotype (9, lo), although the 
development of spontaneous and procainamide-induced 
ANA is a dissociable process. Also, we have found that 
the amount of drug-induced DNA damage in primary 
cultures of intact hepatocytes obtained from rapid and 
slow acetylator rabbits is dependent on the specific 
hydrazine drug or arylamine to which the hepatocytes 
are exposed as well as the acetylator phenotype. 
Acetylator phenotype and ANA 
Twenty inbred strains of mice, including NZB, 
NZW, and NZB/W F, female hybrids, were screened 
for their ability to N-acetylate arylamine substrates. 
The NZB/W F, female hybrid mice are characterized 
by spontaneous appearance of ANA and several other 
complications of human systemic lupus erythematosus 
(1 1). One parental strain, the NZB, is characterized by a 
severe Coombs positive hemolytic anemia while the 
other parent, NZW, is afiparently normal immunologi- 
cally. Although the autoimmune disease of these mice is 
not worsened by lupus-inducing drugs (12,13), the dis- 
by these agents (14-16). 
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Figure 1. Blood PA-NAT activity in rapid and slow acetylators 
@mol/min/mg protein). C57BL/6J and A/J mice can be distin- 
guished on the basis of PA as well as PABA acetylation. Offspring in 
the F2 and backcross populations which were phenotyped as rapid or 
slow acetylators of PABA are also appropriately rapid and slow ace- 
tylators of PA. Correlation coefficient of blood PA-NAT versus 
PABA-NAT activity in F,, F2, and backcross mice was 0.77 (P < 
0.005). Each symbol represents 1 animal. (From J Pharmacol Exp 
Ther 213:485490, 1980. Reproduced by permission.) 
The principal substrates employed for screening 
were p-aminobenzoic acid and sulfamethazine since 
they show unimodal and bimodal populations of acety- 
lation capacity respectively in human and rabbit popu- 
lations (17-19). In this survery, we found that the A/J 
strain is a slow acetylator phenotype (20). A/J mice can 
be differentiated from C57BL/6J mice, a rapid acety- 
lator autoimmune resistant inbred strain selected for 
these characteristics, by several measures of acetylation 
capacity: 1) by little or no detectable N-acetyl- 
transferase activities for p-aminobenzoic acid, pro- 
cainamide (lo), aminofluorene, and benzidine in blood 
(21); 2) by the excretion of less urinary acetyl- 
sulfamethazine after oral administration of sulfametha- 
zine (11.4 f 4.4% for A/J versus 28.3 & 5.5% for 
C57BL/6J) (10); and 3) by an 8-10 fold difference in N- 
acetyltransferase activity for aminofluorene or ben- 
zidine in liver (21). 
Genetic analysis of distributions for F,, F,, and 
backcross progeny for both liver and blood reveals in- 
heritance patterns consistent with segregation at a single 
locus of 2 major codominant autosomal alleles for 
aminofluorene N-acetyltransferase activity. This genetic 
hypothesis is further supported from analysis of re- 
combinant inbred lines developed from A/J and 
C57BL/6J strains (22). 
These observations suggested that A/J mice 
could be a useful model for studying the human lupus 
diathesis since this strain is characterized by a pre- 
disposition to spontaneous and drug-induced ANA and 
by the slow acetylator phenotype. To evaluate the im- 
portance of the slow acetylator phenotype in the lupus 
diathesis, A/J mice were mated with C57BL/6J mice 
and associations were sought between slow acetylator 
phenotype and both spontaneous and procainamide-in- 
duced ANA among offspring from F,, F,, and backcross 
matings. 
Since procainamide was the provocative drug in 
this study, it was important to demonstrate that metabo- 
lism of procainamide reflects the acetylator polymor- 
phism in mice. We showed that in both parental strains 
and animals in the F, and backcross offspring slow or 
rapid p-aminobenzoic acid acetylators were also slow or 
rapid acetylators of procainamide (Figure 1). However, 
no appreciable differences in either procainamide ace- 
tylation in vitro by liver and certain other tissues or by 
procainamide acetylation in vivo was apparent between 
the parental strains. 
Mice 3 months of age were provided procain- 
amide in the drinking water at a concentration suf- 
ficient to supply 20 mg/kg/day. ANA determinations 
were made in each mouse throughout the 37 weeks of 
the study of untreated and procainamide-treated mice 
as an indication of the autoimmune process occurring 
either spontaneously or as a result of procainamide ad- 
ministration. An indirect slide test for ANA was em- 
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Figure 2. Whole-life ANA scores of parental type animals. Whole- 
life ANA score is the sum of 8 determinations per mouse during the 
37 weeks of the experiments. Individual tests were graded by using 
the scale previously described (10). A/J mice (both sexes) had higher 
whole-life ANA scores than C57BL/6J mice (2 = 5.4; 2 > 3.8 is sig- 
nificant, P < 0.05). (From J Pharmacol Exp Ther 213:485490, 1980. 
Reproduced by permission.) 
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ployed which utilizes a peroxidase-conjugated rabbit 
antimouse IgG to visualize ANA deposited in the nu- 
clear substrate (23). 
By using this test we codinned the findings of 
Ten Veen and Feltkamp (14) that A/J mice have a 
higher incidence of ANA-positive sera spontaneously 
than C57BL/6J mice (Figure 2). It was also noted that 
ANA responsiveness is probably a genetic trait since 
backcrosses with the A/J parent produced offspring 
with greater ANA positivity than offspring from back- 
crosses with C57BL/6J parents (Figure 3). Whole-life 
ANA scores, the sum of 8 ANA determinations in each 
mouse, also support the difference in ANA positivity 
between strains (Figure 4). It is also evident from the 
whole-life ANA scores in the F, generation that an asso- 
ciation still occurs after two generations between slow 
acetylator phenotype and high titers of spontaneous 
ANA. 
Effects of procainamide exposure on whole-life 
scores can be seen in Figure 5. Data in Figure 5 from 
procainamide-treated mice (open-circles) show a shift to 
the right indicating that ANA levels are induced in A/J 
mice by procainamide as Ten Veen and Feltkamp (14) 
observed. Contrary to their observations, however, we 
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Figure 3. ANA responsiveness in parental lines and their back- 
crosses. a, Average percentage of positive ANA tests for all animals of 
a given type; 8 determinations per animal. Backcross animals were 
pooled on the basis of negative findings for sex and drug treatment. b, 
2 values are computed on the basis of the average percentage of posi- 
tive ANA reactions and the total number of determinations (from 320 
to 636 per group). y > 3.8 is significant, P < 0.05. (From J Pharmacol 
Exp Ther 213:485-490, 1980. Reproduced by permission.) 
found that procainamide significantly suppressed ANA 
titers in C57BL/6J mice as shown by the shift of the 
open circles to the left. Phenotypic slow acetylator off- 
spring, unlike their slow acetylator (A/J) parents, 
showed procainamide-suppression of ANA scores, 
while ANA titers in rapid acetylator offspring were 
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Figure 4. Whole-life spontaneous ANA scores in rapid and slow acetylator mice. High spontaneous 
ANA scores were associated with the S phenotype as found in the A/J parental strain. Phenotypic S mice 
had significantly higher whole-life spontaneous ANA scores than R (2 = 4.80), A/J (2 = 13.1), or 
C57BL/6J mice (2 = 5.4). 2 > 3.8 is significant, P < 0.05. Each symbol represents 1 animal. (From J 
Pharmacol Exp Ther 213:485-490, 1980. Reproduced by permission.) 
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Figure 5. Effect of PA administration on whole-life ANA scores. Chronic PA administration (0) ele- 
vated ANA scores in A/J mice (2 = 10.7) and depressed scores in C57BL/6J mice (2 = 5.6). Phenotypic 
S mice, unlike their slow acetylator parents (A/J), showed PA suppression of ANA scores (2 = 9.1) in- 
dicating the genetic independence of acetylator phenotype from PA-inducible ANA. PA had no effect on 
ANA scores of R mice. 2 > 3.8 is significant, P c 0.05. Each symbol represents 1 animal. (From J Phar- 
macol Exp Ther 213:485490, 1980. Reproduced by permission.) 
unaffected by exposure to procainamide. These findings 
suggest that spontaneous and procainamide-induced 
ANA in mice are dissociable processes and that the slow 
acetylator phenotype is associated with spontaneous oc- 
currence of ANA, perhaps as a genetic marker. On the 
other hand, a possible causal relationship is not ex- 
cluded even though such a relationship is not apparent 
from these studies. 
The unexpected occurrence of ANA suppression 
in C57BL/6J mice and slow acetylator F, offspring de- 
rived from C57BL/6J parents raises some interesting 
questions about the mechanisms by which procain- 
amide alters ANA titers. Although the slow acetylator 
phenotype is a liability in human drug-induced lupus, 
this seems not to be the case in mice. Perhaps slow ace- 
tylator phenotypes do not have elevated levels of pro- 
cainamide or have such high spontaneous ANA titers 
that they cannot be induced further. Of interest in con- 
nection with the data we report are the observations 
that the severe autoimmune state of NZB was not wors- 
ened by the lupus-inducing drugs either (12,13). 
Procainamide-induced ANA suppression also 
raises the possibility that procainamide itself might be 
cross reactive with nuclear antigens and thus block 
ANA reactions in mice having the drug in their serum. 
Moreover, such cross reactivity, should it be demon- 
strable, might be the means by which procainamide in- 
duces ANA. This hypothesis of cross reactivity seems 
unlikely, however, since none of the sera from control 
or procainamide-treated mice had anti-procainamide 
antibodies irrespective of ANA titers, nor did pro- 
cainamide added directly to ANA-positive mouse 
serum pools alter their titer. 
We have suggested a more speculative mecha- 
nism for drug-induced ANA (10) i.e., that drugs capable 
of inducing lupus have a distinct phamacologic prop- 
erty which enables them to act directly on the immune 
system either in unchanged form or through metabolites 
and that the ability of the immune system to respond to 
this property is subject to genetic variability which ap- 
pears to covary with the slow acetylator trait. In support 
of such a possibility it has been proposed that loss of a 
population of suppressor T cells accompanies autoim- 
mune susceptibility in mice (24,25) and that replenish- 
ment of these cells can prevent or reverse some autoim- 
mune phenomena (26). Perhaps this population of cells 
is “weak” in some strains and “strong” in others and the 
lupus-inducing drugs being toxic to or suppressive of 
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these cells, affect the weak strains more readily. (See 
addendum.) 
Dependence of DNA damage on acetylator 
phenotype and substrate specificity 
Tissue disorders that characterize drug-induced 
lupus are believed to be mediated by antibodies to nu- 
cleic acids, nucleoproteins, or both (27,28) but very little 
appears to be known about the mechanism by which 
these antibodies are produced. Should adducts be 
formed between lupus-inducing drugs (or their metabo- 
lites) and nuclear components, this could either alter the 
DNA of recipient cells to increase its antigenicity or al- 
ter the nuclear components of recipient immune systems 
to induce immune nonresponsiveness. Either of these 
mechanisms might account for the effects seen in drug- 
induced lupus. 
Formation of adducts between a lupus-inducing 
drug and nuclear components might occur directly (29) 
although a great deal of evidence has been accumulated 
during recent years to indicate that the toxicologic ac- 
tions of many injurious chemicals including pro- 
cainamide (30) involve metabolic activation ultimately 
resulting in combination between reactive metabolites 
of the chemical and macromolecules of the host tissues. 
A propos of such reactions involving lupus-inducing 
drugs, Lorand et a1 (31) have observed that hydralazine 
and isoniazid are excellent substrates for plasma trans- 
glutaminase and are incorporated into serum proteins. 
Recently Buxman (32) has extended this work to in- 
clude intracellular epidermal transglutaminase by 
showing that albumin and nucleoproteins are excellent 
acceptors of these drugs and that the drug-albumin and 
drug-histone conjugates formed are highly antigenic, 
eliciting drug-specific antibodies in immunized rabbits. 
These investigations are relevant to the problem of 
drug-induced lupus although they do not account for 
the role of the acetylator phenotype as a possible etiol- 
ogic factor in the production of the antibodies associ- 
ated with this disorder. 
Recently our laboratory has been interested to 
discern whether there is a correlation between the ge- 
netic differences in individual N-acetylating capacity of 
arylamines such as aminofluorene and differences in 
nucleic acid adduct formation (33). Enzymatic activa- 
tion of aminofluorene is a complex process involving N- 
acetylation, N-hydroxylation, and esterification. Two 
steps in this process, separated by N-hydroxylation, in- 
volve N-acetyl transfer: 1) the CoASAc-dependent for- 
mation of amides via N-acetyltransferase, and 2) the 
CoASAc-independent generation of reactive N-ace- 
toxyarylamines from arylhydroxamic acids via aryl- 
hydroxamic acid N,O-acetyltransferase. The latter en- 
zyme removes the N-acetyl group of the hydroxamic 
acid and produces a reactive species capable of forming 
arylamine-nucleic acid and protein adducts (34). 
Comparison of the properties of this acetyl- 
transferase with those of the CoASAc-dependent N- 
acetyltransferase revealed a number of similarities. Sub- 
sequently we showed that 1) both activities were high in 
rapid acetylator rabbits and low in slow acetylator rab- 
bits; 2) they could not be resolved by various protein 
purification techniques which exploit differences in sol- 
ubility, charge, and size; and 3) they both migrated as a 
single symmetrical protein band on polyacrylamide gel 
electrophoresis. Thus it appears that the enzyme respon- 
sible for arylamine-nucleic acid adduct formation and 
the genetically polymorphic N-acetyltransferase are 
properties of the same enzyme in rabbit liver. 
These findings suggested that hepatocytes from 
rapid and slow acetylator rabbits might be useful in de- 
termining whether DNA damage induced by substances 
such as hydralazine and 2-aminofluorene is dependent 
on acetylator phenotype. A number of short-term tests 
have been devised to evaluate the potential of specific 
chemicals for genotoxic effects (35). One of these, the 
hepatocyte primary culture (HPC/DNA) repair test, as- 
sesses chemically induced DNA damage by measuring 
3H-thymidine incorporation by autoradiography during 
DNA repair in freshly isolated hepatocytes in mono- 
layer cell culture. Intact hepatocytes were isolated from 
rabbits of both acetylator phenotypes by collagenase 
perfusion and DNA damage was assessed. Previous 
studies had shown that the genetic N-acetyltransferase 
polymorphism seen in intact rabbits and liver homoge- 
nates (18) was also seen in the isolated hepatocytes (36). 
Preliminary results from an experiment in which he- 
patocytes were exposed to a range of hydralazine con- 
centrations ( 10-5-10-zM) showed that the amount of 
DNA damage depends on the hydralazine concentra- 
tion to which cells are exposed. In the same experiment 
unscheduled DNA synthesis was seen in the slow acety- 
lator hepatocytes exposed to lO-’M hydralazine but not 
in rapid acetylator hepatocytes exposed to 5 X lO-’M 
hydralazine. (HPC/DNA repair test was carried out by 
Dr. C. A. McQueen and Dr. G. M. Williams of the 
Naylor Dana Institute for Disease Prevention, Ameri- 
can Health Foundation, Valhalla, New York.) This sug- 
gests that slow acetylation augments the genotoxic ef- 
fect of hydralazine. 
In a similar experiment employing various con- 
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centrations of 2-aminofluorene, unscheduled DNA syn- 
thesis occurred in rapid acetylator hepatocytes exposed 
to 10-4M 2-aminofluorene while it was barely detected 
in slow acetylator hepatocytes at that concentration of 
the arylamine. Thus, rapid acetylator hepatocytes were 
more sensitive to 2-aminofluorene-induced genotoxicity 
than slow acetylator hepatocytes. Additionally, it is evi- 
dent that DNA damage in rapid and slow acetylator 
rabbit hepatocytes depends on the acetylator phenotype 
for both of the compounds tested, although the degree 
of DNA damage resulting from exposure to hydralazine 
is greater in slow acetylator hepatocytes while the oppo- 
site appears to be the case for 2-aminofluorene. 
Evidently differences in chemical structure must 
be regarded as critical determinants of DNA damage 
under the conditions of this test. Although this con- 
clusion is not entirely unexpected, we believe that this is 
the first demonstration of a difference in DNA damage 
related to the acetylator phenotype difference. The 
mechanism by which the observed differences were gen- 
erated is not established although it is reasonable to ex- 
pect their explanation may lie in differences in the me- 
tabolism of hydralazine and 2-aminofluorene and 
possibly in reactive metabolites derived from them. 
Such considerations should also take account of differ- 
ences in reactivity of nucleic acid components and other 
macromolecules for induced metabolites. It may be per- 
tinent in connection with this possibility that hydrazine, 
another agent that has been reported to induce a lupus- 
like state (37), specifically reacts with pyrimidine bases 
of DNA but not with purine bases (38,39). 2-Amino- 
fluorene-nucleic acid adducts, on the other hand, are 
formed through purine (guanosine) bases (34). 
We conclude that acetylator phenotype can af- 
fect adduct formation between nucleic acids and lupus- 
inducing drugs such as hydralazine and that such a 
mechanism may occur in human beings and partially 
account for the predisposition of slow acetylators to 
hydralazine-induced lupus. 
Addendum 
Evidence for a cellular rather than an antigen- 
based mechanism has recently been obtained. Serum 
from patients treated with PA suppressed Con A mi- 
togenesis in cultures of peripheral blood mononuclear 
cells, but serum from N-acetylprocainamide-treated pa- 
tients did not. This effect could not be seen by adding 
either drug to normal serum. Conversion of a greater 
portion of procainamide to its acetylated metabolite 
could thereby confer a degree of protection from the 
PA-induced inhibitory factor. The nature of this inhib- 
itory factor is not known. However, it is significant that 
serum from SLE patients also specifically inhibits Con 
A mitogenesis. This common feature of spontaneous 
and PA-induced SLE may ultimately be related to the 
functional loss, by either a genetic or pharmocologic 
mechanism, of a small population of suppressor T cells 
which have been linked to autoimmunity. (Tannen RH, 
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Dr. Talal: It may be possible to augment the difference 
between C57BL and A/J by the introduction of a 
new element, namely, the drug procainamide. Your 
experimental manipulation, in this case by giving the 
drug, in another case the breeding experiment, may 
be intensifying a defect which perhaps is only mini- 
mal in its natural setting. In rheumatology we think 
in terms of multifactorial etiologies of disease. This 
would be an exteremely important point. 
Dr. Weber: This apparent augmentation may be due to 
the way the data are presented. In Figures 4 and 5, 
which showed the increase in the titer with time for 
slow and rapid versus the two parental strains, the ti- 
ter of the animal is noted at a given point in time, for 
example at the end of 35 or 36 weeks. This method of 
determination is the way that Ten Veen and Felt- 
kamp expressed their information. We found, how- 
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ever, that by measuring titers throughout the course 
of the lifetime of the animals when they were taking 
procainamide, we could get more information from 
the data. We had 8 data points instead of one for 
analysis. The actual division point in time when the 
animal began to respond changed a bit; that is, in the 
case of the slow or the A/J parental lines, it may have 
taken a few weeks before any response occurred. We 
could then conclude that there was no difference in 
that part of the response from no exposure and in- 
clude that in either the weak responder or non/non- 
responder stage. Then it was clear from the time 
course that the response began to increase quite rap- 
idly in the slow animals. 
Dr. Alarcon-Segovia: There is a study that may be per- 
tinent in which A/J mice were changed from one en- 
vironment to another and started producing anti- 
nuclear antibodies. 
Dr. Shulman: In the early sixties Friou obtained pooled 
sera from 9 different inbred strains at the Jackson 
Laboratory and reported that the A/J strain was the 
only 1 of these 9 strains that had antinuclear anti- 
body, which was found in about 25% of the animals 
(Friou GJ, Teague PO: Arthritis Rheum 6:773-774, 
1963). I then requested some A/J animals from the 
Jackson Laboratory. As a genetically related strain 
the A Heston was chosen, which you showed as your 
second strain. We also asked for a genetically unre- 
lated strain, the C57BL/6J. 
We found a 25% incidence of ANA in the A/J, 
22% in the C57BL/6J, and 39% in the A/He, the ge- 
netically related strain. So we suspected an environ- 
mental factor. We found that the incidence of ANA 
was much lower in mice from Cumberland Farms in 
Tennessee, 5% and 3% compared to the 22% and 39% 
in the animals from Jackson Labs (Shulman LE et al: 
Arthritis Rheum 7:78, 1964). 
Dr. Heston at the Cancer Institute informed us 
that he had donated these strains to the Cumberland 
Farms and thus considered that the genetic makeup 
was the same. We cross-grafted skin from the A/He 
strain animals from the Cumberland Farms and the 
Jackson Labs, and grafts were successful. That expe- 
rience may indicate some environmental differences 
from producer to producer. Perhaps, Dr. Weber, 
some of your differences with Dr. Feltkamp might be 
related to animal source. Are your animals from 
Jackson Labs? 
Dr. Weber: Yes, they were. Dr. Feltkamp’s animals 
were from Jackson Laboratories and were shipped to 
Holland and maintained there, so the environment 
was not the same. Certainly the enzymes responsible 
for drug metabolism are highly affected by the envi- 
ronment. In this case, I do not know of any available 
definitive evidence. 
Dr. Talal: Dr. Lloyd Old at the NIH Cancer Institute 
and I were interested in the age and sex dependent 
development of antiDNA and antiRNA antibodies. 
We had our NZB and B/W mice in two buildings: 
our main colony in the Clinical Center and a second 
colony in Lloyd Old’s building at the Cancer Insti- 
tute. We took blood samples from both groups and 
analyzed them separately. 
There was a significantly earlier onset of de- 
velopment of autoantibodies and a higher incidence 
of autoantibodies in the mice housed in the Cancer 
Institute building as compared with those in the Clin- 
ical Center. The other work in the Cancer Institute 
building dealt extensively with oncogenic viruses. 
This is an anecdote, but one factor we consid- 
ered important for this difference was the presence of 
oncogenic and other viral agents in the Cancer Insti- 
tute Building. 
Dr. Weber: All of the mice in my studies were main- 
tained in a separate room throughout the experiment. 
So the environment was fairly constant across the 
group. The differences seen here should be related to 
drug exposure. 
Dr. Tan: Dr. Weber, there appears to be a difference in 
hepatocyte activity between mouse and rabbit. 
Dr. Weber: There is a big difference in acetylating ca- 
pacity between mouse and rabbit. There can be a sev- 
eral hundredfold difference in liver activity between a 
rapid and slow acetylator rabbit. The difference be- 
tween A/Js and C57s (the absolute level of activity is 
lower in the mouse strains) for example, with amino 
fluorine as a model substrate is about tenfold. Also, it 
is clear that substrate specificity is involved because 
there is no in vitro difference with procainamide in 
these mouse strains. 
Dr. DubrofE A critical factor is whether incubation,was 
in darkness or light. It should have been in absolute 
darkness; otherwise tremendous variability results 
since this tissue culture reaction is photochemical. 
Dr. Weber: We were concerned about the capability of 
the hepatocytes to repair in the rapid and slow acetyl- 
ator rabbits. So we ran an ultraviolet control. The ca- 
pacity of the hepatocyte to repair DNA was precisely 
the same in the rapid and the slow acetylators. This 
large difference does exist for the two substances, but 
the differences are in opposite directions. 
Dr. DubrofE A photochemical reaction is markedly en- 
hanced by certain wavelengths of light. In this case, it 
is 290 nanometers to about 330 nanometers. If you 
did not prepare these in absolute darkness, your reac- 
tion would be in part photochemical. Another prob- 
lem is the incubation media. Hydralazine is suscep- 
tible to degradation in the presence of divalent 
cations. 
Dr. Weber: We did put hydralazine in and the differ- 
ence is related to hydralazine dose, although we don’t 
know specifically what is occurring or how many dif- 
ferent steps in the breakdown of hydralazine may 
have taken place before it produced damage. These 
experiments were performed in the absence of light, 
